Category:

Release – CoreCivic Announces 2022 First Quarter Earnings Release and Conference Call Dates

Posted on by Admin



CoreCivic Announces 2022 First Quarter Earnings Release and Conference Call Dates

Research, News, and Market Data on CoreCivic

 

BRENTWOOD, Tenn., April 21, 2022 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2022 first quarter financial results after the market closes on Wednesday, May 4, 2022.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 5, 2022, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 888-882-4478 in the U.S. and Canada, including the confirmation passcode 8967211. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:15 p.m. central time (2:15 p.m. eastern time) on May 5, 2022, through 1:15 p.m. central time (2:15 p.m. eastern time) on May 13, 2022. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8967211.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024

Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1

Posted on by Admin



electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

News and Market Data on electroCore

 

ROCKAWAY, N.J., 
April 21, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire™ in patients admitted to the hospital for treatment of COVID-19. 

The SAVIOR-1 trial was conducted by principal investigator Dr.  Carlos Tornero, Head of the 
Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de 
Valencia, Spain, between 
April 2020 and 
February 2021. The trial targeted patients over 18 years of age and enrolled 110 patients, randomly assigned, with 55 patients in each group. Of the 110 patients, 97 patients (47 in the nVNS treatment group, 50 in the control group) provided baseline demographic and medical history data and were the evaluable population. The study evaluated the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with the standard of care alone.

The study identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein (CRP) levels were significantly greater in the nVNS treatment group as compared to the control group throughout the five-day period combined (p=0.011) and on day 5 compared to the day 1 baseline period alone (p=0.015). On day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control (p=0.010). Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 (p=0.012) as compared to the control group. Increased levels of CRP, procalcitonin, and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms.

nVNS was well tolerated with no major device-related adverse events and the therapy was administered three times daily to most patients as outlined in the study protocol.

“We are thrilled that the SAVIOR-1 article has been peer-reviewed and published in the Frontiers in Neurology journal,” mentioned Dr.  Peter Staats, Chief Medical Officer at electroCore. “We are encouraged by this publication as Frontier’s rigorous process for peer-reviewing articles further strengthens and validates our nVNS technology and its relevancy and potential to mitigate some of the symptoms associated with COVID-19.” 

The Frontiers in Neurology publication is available here.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore (nVNS) is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:

  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Adolescent patients with congenital cardiac issues
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

For more information, please visit gammaCore.com

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, the results from investigator-initiated trials, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the
SEC, available at www.sec.gov.

Contact:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Release – Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases

Posted on by Admin



Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19. Cocrystal applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors. Under the NIAID collaboration, Cocrystal has provided its 3CL protease inhibitors, and the NIAID will be responsible for in vitro and in vivo studies evaluating the antiviral activity of the compounds.

“We are pleased to collaborate with NIAID to further evaluate Cocrystal’s SARS-CoV-2 3CL protease inhibitors. Cocrystal is committed to identifying safe and effective treatments for infectious diseases including those caused by SARS-CoV-2 and other coronaviruses,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “We are pleased that the NIAID has researched our novel, broad-spectrum protease inhibitors and has determined that further evaluation in an animal model is warranted. Studies to date show that our protease inhibitors exhibit superior in vitro potency against SARS-CoV-2 and variants of concern including Omicron.”

A division of the National Institutes of Health (NIH), NIAID conducts and supports basic and applied research to better understand, treat and ultimately prevent infectious, immunologic and allergic diseases. Dr. Anthony S. Fauci, M.D. was appointed Director of the NIAID in 1984. More information is available at niaid.nih.gov/.

About Cocrystal SARS-CoV-2/Coronavirus Programs
Cocrystal is developing COVID-19 drug candidates that specifically target proteins involved in viral replication. Despite the various strains of virus that may exist or emerge, these enzymes are required for viral replication and are essentially similar (highly conserved) among all strains. By targeting these highly conserved regions of the replication enzymes, Cocrystal’s antiviral compounds are designed and tested to be effective against major virus strains. Additionally, Cocrystal believes it is possible to develop an effective treatment for all coronavirus diseases including COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The Company’s main SARS-CoV-2 protease inhibitors showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our collaboration with NIAID and our ability to develop an effective treatment for all coronavirus diseases. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of the COVID-19 pandemic and the Russian invasion of Ukraine on the global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, the results of NIAID’s preclinical research of our 3CL protease inhibitors for the treatment of COVID-19, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – Alvopetro Announces Discovery at 182-C1 Well

Posted on by Admin



Alvopetro Announces Discovery at 182-C1 Well

Research, News, and Market Data on Alvopetro Energy

 

CALGARY, AB, April 21, 2022 /CNW/ – Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) announces that we have completed drilling the 182-C1 well on our 100% owned and operated Block 182 in the Recôncavo basin. Based on open-hole wireline logs the well has discovered 25 metres of potential net natural gas pay, with an average porosity of 8.2%.

President and CEO, Corey Ruttan commented:

“Preliminary drilling results from our 182-C1 well represent the first successful step in our organic growth strategy to expand our natural gas business in Brazil. We are currently increasing the capacity of our gas processing facility and we look forward to testing this well to understand the full development and production growth potential relating to this exciting new discovery.”

The 182-C1 well was spud on March 2, 2022 and drilled to a total measured depth (“MD”) of 2,926 metres. Two open-hole logging runs were completed and based on the open-hole logs, the 182-C1 well encountered a 36-metre-thick Agua Grande Formation sand at 2,550 to 2,586 metres total vertical depth with 25 metres of potential net natural gas pay, at an average 34% water saturation and average porosity of 8.2%, using a 6% porosity cut-off, 50% Vshale cut-off and 50% water saturation cut-off.  Neutron-density crossover on logs is interpreted to be reflective of natural gas pay but will be confirmed with well testing.

The primary and secondary targets of the 182-C1 well were the Agua Grande and Sergi Formations, respectively. Based on preliminary drilling results, the 182-C1 well encountered net pay in the Agua Grande Formation but did not encounter the Sergi Formation, the secondary target, due to the well crossing a normal fault before reaching the Sergi Formation. Data obtained from drilling the 182-C1 well is expected to assist in drilling follow-up development Agua Grande wells that will also be designed to reach the Sergi Formation further east from the bounding fault.   

Based on these drilling results, we plan to undertake a testing program of the 182-C1 well with a service rig, subject to customary regulatory approvals and equipment availability. This additional testing will assess the productive capability of this well and help define the field development plan. 

After running casing, we plan to mobilize the drilling rig to our next exploration location, the 183-B1 well, which is expected to be spud in May. The 183-B1 well also targets the Agua Grande and Sergi Formations as the primary and secondary targets, respectively.  

Corporate Presentation

Alvopetro’s updated corporate presentation is available on our website at:

http://www.alvopetro.com/corporate-presentation.

Social Media

Follow Alvopetro on our social media channels at the following links:

Twitter – https://twitter.com/AlvopetroEnergy
Instagram – https://www.instagram.com/alvopetro/
LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltd
YouTube – https://www.youtube.com/channel/UCgDn_igrQgdlj-maR6fWB0w

Alvopetro Energy Ltd.’s vision is to become a leading independent upstream and midstream operator in Brazil. Our strategy is to unlock the on-shore natural gas potential in the state of Bahia in Brazil, building off the development of our Caburé natural gas field and our strategic midstream infrastructure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

All amounts contained in this new release are in United States dollars, unless otherwise stated and all tabular amounts are in thousands of United States dollars, except as otherwise noted.

Cautionary statements regarding the filing of a Notice of Discovery. We have submitted a Notice of Discovery of Hydrocarbons to the Agência Nacional do Petróleo, Gás Natural e Biocombustíveis (the “ANP”) with respect to the 182-C1 well. All operators in Brazil are required to inform the ANP, through the filing of a Notice of Discovery, of potential hydrocarbon discoveries. A Notice of Discovery is required to be filed with the ANP based on hydrocarbon indications in cuttings, mud logging or by gas detector, in combination with wire-line logging. Based on the results of open-hole logs, we have filed a Notice of Discovery relating to our 182-C1 well. These routine notifications to the ANP are not necessarily indicative of commercial hydrocarbons, potential production, recovery or reserves.

Testing and Well Results.  Data obtained from the 182-C1 well identified in this press release, including hydrocarbon shows, open-hole logging, net pay and porosities, should be considered to be preliminary until testing, detailed analysis and interpretation has been completed. Hydrocarbon shows can be seen during the drilling of a well in numerous circumstances and do not necessarily indicate a commercial discovery or the presence of commercial hydrocarbons in a well. There is no representation by Alvopetro that the data relating to the 182-C1 well contained in this press release is necessarily indicative of long-term performance or ultimate recovery. The reader is cautioned not to unduly rely on such data as such data may not be indicative of future performance of the well or of expected production or operational results for Alvopetro in the future.

Forward-Looking Statements and Cautionary Language. This news release contains “forward-looking information” within the meaning of applicable securities laws. The use of any of the words “will”, “expect”, “intend” and other similar words or expressions are intended to identify forward-looking information. Forward?looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the expectations discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events. Accordingly, when relying on forward-looking statements to make decisions, Alvopetro cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties. More particularly and without limitation, this news release contains forward-looking information concerning potential natural gas pay in the 182-C1 well, exploration and development prospects of Alvopetro and the expected timing of certain of Alvopetro’s testing and operational activities. The forward?looking statements are based on certain key expectations and assumptions made by Alvopetro, including but not limited to expectations and assumptions concerning testing results of the 182-C1 well, equipment availability, the timing of regulatory licenses and approvals, the success of future drilling, completion, testing, recompletion and development activities, the outlook for commodity markets and ability to access capital markets, the impact of the COVID-19 pandemic, the performance of producing wells and reservoirs, well development and operating performance, foreign exchange rates, general economic and business conditions, weather and access to drilling locations, the availability and cost of labour and services, environmental regulation, including regulation relating to hydraulic fracturing and stimulation, the ability to monetize hydrocarbons discovered, the regulatory and legal environment and other risks associated with oil and gas operations. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. Although Alvopetro believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Alvopetro can give no assurance that it will prove to be correct. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on factors that could affect the operations or financial results of Alvopetro are included in our annual information form which may be accessed on Alvopetro’s SEDAR profile at www.sedar.com. The forward-looking information contained in this news release is made as of the date hereof and Alvopetro undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

www.alvopetro.com TSX-V: ALV, OTCQX: ALVOF

SOURCE Alvopetro Energy Ltd.

Release – Garibaldi – Nickel Mountain Ztem Survey Identifies New Pipe-Like Target

Posted on by Admin



Nickel Mountain Ztem Survey Identifies New Pipe-Like Target

Research, News, and Market Data on Garibaldi Resources

 

Vancouver, British Columbia, April 21, 2022 – Garibaldi Resources (TSXV: GGI) (the “Company” or “Garibaldi”) is pleased to announce that further to the company’s 2021 ZTEM survey results (see news release March 31, 2022) at Nickel Mountain in the Eskay Camp of northwest British Columbia, 3D processing has identified several new low-resistivity ZTEM responses located 5 km northeast of the E&L nickel-copper-cobalt massive sulphide zone, including an exciting new anomaly at target B1/White Fox.

The flagship E&L project generated especially promising deep penetrating ZTEM data providing renewed focus on several drill targets to test the large geophysical anomalies beneath and along trend from E&L, for mineralization. The ZTEM survey over the remainder of the claim group also identified an unexpected alignment of high priority targets, with similar features. The B1 ZTEM anomaly which rises from a great depth like E&L, extends vertically up to the B1 VTEM conductor near surface.

Several other features elevate the B1 target to high priority status besides the coincidence of a ZTEM anomaly with a VTEM conductor. The presence of gabbroic intrusions of the Nickel Mountain Complex, and numerous in-situ surface samples and mineralized boulder train samples with elevated copper, zinc and lead over a broad 3km strike length. Also, elevated MgO concentrations up to levels found at the E&L intrusion, along with anomalous nickel, indicating the potential for magmatic sulphides.

The ZTEM data for the B1 target, which has not been drill tested provides a key target for the 2022 property scale field program which is highlighted by the following observations:

  • The property-wide ZTEM survey has identified several low-resistivity responses that plunge to considerable depth, and also correlate with the location of near surface conductors from the 2017 and 2018 VTEM surveys. Coinciding ZTEM and VTEM anomalies offer strong support for the B1 target. The ZTEM response rising to surface from great depth, may be highly significant.
  • Similar low-resistivity responses to those beneath the E&L mineralized zones continue along a 15 km long trend of gabbroic intrusions within the Hazelton Group, striking to the northeast towards Mount Shirley. A corridor within this belt of coincident ZTEM-VTEM responses with clusters of samples containing elevated Base Metals, aligns over a 3 km trend.
  • The modelled ZTEM responses along strike coincides with base metal assays from in-situ samples and boulder trains with elevated nickel, copper and zinc. Additional conductive data supports an alignment along the northeast strike of E&L extending over and continuing past B1.

The primary exploration focus will be on the robust ZTEM-VTEM targets supported by geochemistry, and located along strike from E&L. Garibaldi will provide shareholders with more forthcoming analysis of the most prominent amongst the notable dozen new ZTEM anomalies at Nickel Mountain, as they become available.

Figure 1 Anomaly B1: White Fox displays a consistent ZTEM low resistivity zone coincident with a near surface VTEM conductive anomaly. The ZTEM low resistivity zone extends to great depths, similar to the low resistivity zone beneath E&L.

Jeremy Hanson, Garibaldi’s VP Exploration, stated: “We now have numerous ZTEM anomalies corresponding to VTEM conductors, coupled with elevated surface base metal content in samples along a significant trend. This season we will be able to hone in on the highest priority targets, for possible drill testing, likely starting with B1.”

Steve Regoci, Garibaldi’s CEO, stated: “We look forward to a very productive 2022 exploration season, better than expected ZTEM results have identified over a dozen significant ZTEM responses to test. These prospective targets beginning at E&L are large with deep roots, providing significant potential for further discoveries at Nickel Mountain as strong nickel and battery metal prices continue rising.”

Please see www.garibaldiresources.com/investor/presentations/ for more details.

Qualified Person

James Hutter, P.Geo., qualified person as defined by NI- 43-101, has supervised the preparation of and reviewed and approved of the disclosure of information in this news release.

About Garibaldi

Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.

We seek safe harbor.

GARIBALDI RESOURCES CORP.

Per: “Steve Regoci”
Steve Regoci, President

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or the accuracy of this release

No Punches Pulled at NobleCon18 Panel Discussion

Posted on by Admin 


Image Credit: NobleCon (4/20/2022)


Panelists Pulled No Punches at NobleCon18 Discussing ESG, Politics, Inflation, and War

 

Is the world going through a financial, political, and logistical phase that will forever change investment markets? This was not the name given to the panel discussion that closed the first day of presentations at NobleCon18. The actual title was more directly, The World Is HOT Right
Now! The room full of investors was treated to insights by panelists from the world of energy, banking, retail, and the U.S. military. Mike Gallagher, the host of the Mike Gallagher radio show, made sure the panelists didn’t pull any punches as they agreed and disagreed on subjects as hot as political unrest, supply chain constraints, the ESG movement, inflation, and War.


The Line-up

Radio Personality, Host of the Mike Gallagher Show (Moderator)

Brigadier General Blaine Holt, Deputy US Military Representative to NATO (Panelist)

Rani Selwanes, Noble’s Head of Investment Banking (Panelist)

Chuck Rubin, former Chairman & CEO, Michaels (Panelist)

Mark Chalmers, CEO, Energy Fuels (Panelist)


ESG Movement

Mike Gallagher began the discussion with the day’s big news story that Disney (DIS) could lose its special district privileges in Florida. This would cost the public company dearly. He dovetailed this into the discussion of companies taking a strong stance on subjects that come under the mantle of ESG.

None of the panelists shied from discussing their take on the topic as the former CEO of Michael’s pointed out that management’s job is to make money, and that they should do this in a way that has a good impact. He relayed a story where the craft giant he ran, that sold items that averaged between $7-$8, saved on costs, and helped the environment by using less packaging. The overall message was to serve your customers in a way that benefits society. Don’t cater to the PR benefit, instead, do what makes sense.

The investment banker on the panel discussed the movement from an investor’s standpoint. He discussed many examples where issuers, particularly in the fixed income market are being required by investors and asset managers for their ESG policies.


Geopolitical Events and War

The Brigadier General was brought into the conversation as Mike Gallagher pointed out that this is the first time since the 1980’s that the words “World War III” and possible “nuclear war” is being used. The General made sure the investor crowd was aware that President Putin had sold all of Russia’s holding of U.S. Treasuries in 2018. He told the listeners that they should teach military officers more about economics because Russia then proceeded to increase its gold position to $140 billion worth. The point was that this aggression has been going on for the past eight years, and only recently has it reached a point where it’s being recognized.

The concern raised by a few panelists is that Ukraine and Russia provide 30% of the world’s wheat. Conditions could reach a point where there is famine, and in the past, those conditions lead to war.

The CEO of an energy company explained to the attendees that we have become addicted to “cheap.” By this, he explained we are always shopping for the lowest price, and not building at home. With this, a country allows its capacity to wain and leaves them relying on others, potentially future enemies. One notable example given was that we no longer enrich uranium anyplace in the United States. We rely on unfriendly nations for enriching nuclear fuel and even weapons-grade material. The expression used by the CEO was, “digging a hole that you don’t have a ladder to climb back out of.”


Inflation

Rising prices is more than just supply chain issues. We have been creating money which has been our answer to every problem. Instead, we need to build our way out of challenges. From the military point of view, it was explained that the higher inflation goes, the more national security is threatened.

The conversation moved to why people aren’t going back to work. While there was no definitive explanation, it was clear the panelists are perplexed that it is not likely to lead to a soft landing of the economy. The basic cost of living is rising, workers at the lowest levels are able to command much higher wages, and it is very difficult to attract employees which is inflationary.


Take Away

While this discussion hit on many difficult realities, and the panelists, to their credit took them head-on, the silver lining was pointed out to the investors at the end.

The Head of Investment Banking at Noble Capital Markets called upon his international knowledge and experience to remind the audience of something important. He told investors that during periods of turmoil capital experiences a “flight to quality.” That quality has historically been to the U.S., the largest receiver of capital when the world senses enhanced risk. He reminded everyone, including many of the C-level audience members, that there is plenty of capital looking for opportunity in the U.S., they just don’t know where to find you. His advice was to find an advisor (i.e. investment bank) that can help you find this capital.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



What Media Experts Expect from the Metaverse

EV Inflation Outpacing Traditional Cars

 

Stay up to date. Follow us:

 

Release – Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50000 Long COVID Patients

Posted on by Admin



Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients

Research, News, and Market Data on Tonix Pharmaceuticals

 

Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms

Rate of Opioid Use in Long COVID Patients with Multi-Site Pain is a Potential Health Concern

CHATHAM, N.J., April 20, 2022 (GLOBE NEWSWIRE) —  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today the results of a retrospective observational database study in over 50,000 patients diagnosed with Long COVID1-2. Long COVID is known officially as Post-Acute Sequelae of COVID-19 (PASC3). Tonix recently announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 2 clinical trial with TNX-102 SL4 (cyclobenzaprine HCl tablets for sublingual administration) as a potential treatment for a subset of patients with Long COVID whose symptoms overlap with fibromyalgia, and expects to initiate this study in the second quarter. The goal of the retrospective database study was to assess the proportion of Long COVID patients who experience fibromyalgia-like multi-site pain and to measure their use of opiates.

In the study, over 40% of patients with symptoms of Long COVID had fibromyalgia-like multi-site pain 1,2. In addition, the study reported on the rate of opioid use in Long COVID patients. Opioid use noted was in 36% of Long COVID patients with multi-site pain symptoms relative to 19% of Long COVID patients without multi-site pain. In patients with multisite pain, opiate use increased to 39% of patients when fatigue was present, and 50% of patients when insomnia was present.

“We undertook this retrospective analysis in part to determine the feasibility and representative nature of our upcoming Phase 2 study of TNX-102 SL in patients with Long COVID who present with fibromyalgia-like multi-site pain,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The finding that more than 40% of Long COVID patients in this sample have fibromyalgia-like multi-site pain symptoms suggests that we should be able to recruit a robust cohort of participants to test the effects of TNX-102 SL in treating this condition. Further, these findings suggest that the group of Long COVID patients with fibromyalgia-like multi-site pain represents a significant portion of this underserved population. Finally, the high level of opiate use reveals the urgency to provide effective non-opioid analgesia that is targeted toward widespread pain thought to be nociplastic in nature, meaning that augmented CNS pain and sensory processing, as well as altered pain modulation, play a role. The primary efficacy endpoint of the upcoming Phase 2 study will therefore be change from baseline in the weekly average of daily self-reported worst pain intensity scores.”

The study queried data from the TriNetX Dataworks USA Network. The network is a federated network of de-identified inpatient and outpatient electronic medical records from 48 U.S. healthcare organizations. From 75 million people in the network, approximately 1 million adults (18-65) had been diagnosed with acute COVID-19. Of these, approximately 260,000 followed up with a healthcare provider in the network within six months of having acute COVID-19. Of these, approximately 52,000 had Long COVID symptoms in the period between 3 and 6 months after acute COVID-19, which was the time-frame for the analysis for diagnostic codes consistent with multi-site pain, fatigue and insomnia.

1Harris, H, et al. Tonix data on file. 2022
2TriNetX Analytics
3Feb. 24, 2021 – White House COVID-19 Response Team press briefing; Feb 25, 2021 – policy brief from the World Health Organization on long COVID.
4TNX-102 SL is an investigational new drug and has not been approved for any indication.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13006 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
2TNX-2900 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
3TNX-801 is a live horsepox virus vaccine for percutaneous administration in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication.
4TNX-1840 and TNX-1850 are live horsepox virus vaccines for percutaneous administration, in development to protect against COVID-19. TNX-1840 and TNX-1850 are designed to express the SARS-CoV-2 spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. 
5TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
6TNX-1300 is an investigational new biologic and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

About TriNetX, LLC

TriNetX is a global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Release – Direct Digital Holdings to Present at NobleCon18

Posted on by Admin



Direct Digital Holdings to Present at NobleCon18 – Noble Capital Markets’ Eighteenth Annual Investor Conference

Research, News, and Market Data on Direct Digital Holdings

 

HOUSTON, April 19, 2022 /PRNewswire/ — Direct Digital Holdings (Nasdaq: DRCT) today announced that Mark Walker, Chief Executive Officer and Founder of Direct Digital Holdings, and Keith Smith, President and Founder of Direct Digital Holdings, will present at NobleCon18 – Noble Capital Markets’ Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida on Thursday, April 21 at 1:30pm ET.

There is also the opportunity to meet the management team at a breakout session scheduled for Thursday, April 21 at 10:00am ET.

A high-definition, video webcast of the presentation will be available the following day on Direct Digital Holdings’ investor relations website, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek www.channelchek.com, the investor portal created by Noble.

The webcast will be archived on Direct Digital Holdings’ investor relations website, the NobleCon website and on Channelchek.com for 90 days following the event.

About Direct Digital Holdings
Direct Digital Holdings (Nasdaq: DRCT) brings state-of-the-art supply- and demand-side advertising platforms together under one umbrella company. The holding group’s supply-side platform Colossus SSP offers advertisers of all sizes extensive reach within general market and multicultural media properties. Its operating companies Huddled Masses and Orange142 deliver significant ROI for middle market advertisers by providing data-optimized programmatic solutions at scale for businesses in sectors that range from energy to healthcare and travel to financial services. Direct Digital Holdings’ buy-side solutions manages over 200 clients daily, and the sell-side solution serves over 80,000 advertisers generating over 70 billion impressions per month across display, CTV, in-app, and other media channels.

SOURCE Direct Digital Holdings

What Media Experts Expect from the Metaverse

Posted on by Admin


NobleCon18 Brought Media Experts Together to Discuss the Metaverse, Here’s What Happened

 

Media all-star Steve Forbes kicked off this year’s NobleCon18 and the conference’s first panel presentation. Forbes, who is no stranger to changes in media, showed up in the room virtually. This was fitting as the discussion centered around the metaverse. The live panel included all-stars that are on the edge of shaping what is often called Web3. The expert panelists are well-known names in data, gaming, news and information.

No doubt the investors that attended the panel discussion at the Seminole Hard Rock Hotel (Guitar Hotel) left the large room with a better understanding of what the metaverse is, what it can be, and more importantly, where the opportunities are.

Following Steve Forbes’ introduction, the metaverse panel was moderated by Eric Bolling, TV Host of Eric Bolling The Balance. Rob Goldman, a data-driven world-changer who created the model for growth and monetization at Facebook brought his unique insights to the panel. Mike Federle, brought his own experience related to media changing and adapting, as CEO of Forbes Media Group. Christopher Ruddy, the CEO of Newsmax which owns several different news mediums brought well thought out scenarios as to how Web3 will become integrated into our daily lives. And, Dimitry Kozko, CEO, Motorsport Games who understands the important role that gaming has and will continue to play in the growth and normalizing of the metaverse, explained gamings’ critical role in invention and public acceptance.


What was Said

In the coming weeks, Channelchek will post a video broadcast of the panel’s exchange, sign up for Channelchek updates to be sure not to miss the video replay.

Rob Goldman, with his big tech background, reminded the room full of investors that the metaverse is just the next phase of augmented reality. He says this should be comfortable as “we already have a place we go to immerse ourselves in an augmented world.” He sees tech as allowing us to go where we want to go when we want to go. The audience was reminded that smartphones now fit seamlessly into our lives, yet the concept may have been incomprehensible a few short years ago.

Goldman sees the future of the metaverse as split in three ways and perhaps unfolding with heavy input from a few current tech powerhouses. He sees the three segments as hardware & design, technology & partnerships, and network. As for the hardware, Goldman recognizes that the public may not immediately be comfortable with metaverse glasses banding our eyes. He has confidence that Apple (AAPL) which has been tasked before with making abnormal tech changes socially acceptable, can find the successful path to this big challenge. Goldman named Microsoft (MSFT) as having the connections to develop the needed tech partnerships to provide a metaverse that is one day largely connected. The former Facebook head believes Meta (FB) will provide the network piece.

Dmitry Kozko, CEO of Motorsport Games (MSGM) said the digital environment of gaming is helping to bring about the change and acceptance of augmented reality including the metaverse. Kozko described the digital environment as creating understanding and advancing the adoption of augmented reality.

Newsmax’s founder and CEO Chris Ruddy explained that traditional media outlets should be excited to be part of it. He explained the lifecycle of growing tech trends in a way most investors in the room should have taken note of. Ruddy says that the path of previous tech trends was first awareness, followed by a “goldrush,” he said this ushers in capital and resources from which the infrastructure is built. He explained there is then expansion that is followed by a crash as the new industry gets ahead of itself. The new field that will be worth trillions will then regain its footing, building off the infrastructure that was created earlier. Ruddy thinks the metaverse will have its own need for news and his company is excited to be part of this journey.

Mike Federle, CEO of Forbes (OPA) could have added to the discussion from many different angles. As he pointed out, Forbes gets to dip their toe into everyone’s business around the world. This gives him broad insight into most any business discussion. He chose to address the crypto angle of the metaverse. The Forbes CEO suspects the metaverse will bridge the gap for the digital currencies. Federle explains we currently have the crypto-committed (true believers), the crypto curious, and as he explained the crypto-uninitiated. The uninitiated he says is the largest group. Drawing a corollary to the internet’s beginnings (web1), experimentation will lead to adoption. With this, web3 reduces every human interaction into a transaction.


Take-Away

The metaverse presents massive opportunity. One risk is over-speculation, another is government involvement including regulation and probable taxation. Understanding the companies that are getting involved and the contribution they provide is key to investing in what these panelists all believe can grow to become its own world.

NobleCon18 is the 18th annual investor conference held by Noble Capital Markets. The conference which is free to investors will wrap-up all presentations on Thursday April 22. Limited seats are still available.

 

Suggested Content



C-Suite Interview with Forbes Global Media CEO Mike Federle & CFO Mike York

The Metaverse is Under Construction, Here’s What is Known

 

Stay up to date. Follow us:

 

April 20 the Making of a Holiday

Posted on by Admin 


Image Credit: Mike (Flickr)


April 20 Growing as a Day of Cannabis Recognition

 

Did you get your significant other a gift for 4/20 this year? Probably not, it isn’t considered a traditional mainstream gift-giving day like Valentines or Christmas. After all, April 20 recognizes, among other things, the counterculture that didn’t care much for the mainstream. So why would it become commercial in that way — the origin has more to do with a push for access and legalization. But there is a huge uptick in sales leading up to this day. And while many mainstreamers, myself included, only heard of the “420 code” a year or two ago, it is getting far more buzz than ever, and undoubtedly this will be even greater in the coming years.

What it Means for the Industry

Commercial cannabis providers would be missing an opportunity if they didn’t leverage the day’s recognition in a “Cinco de Mayo” meets “St. Patty’s Day” marketing effort. And they are. To confirm this I asked Margot Micallef the founder and CEO of GABY Inc. (GABLF) if 4/20 is a big day for dispensaries. She was gracious enough to take some time away from discussions with investors at NobleCon18 to respond. Ms. Micallef quickly said, “It’s Christmas for cannabis consumers!” She explained, “Consumers wait for it with anticipation and retailers love it because it brings consumers into their stores.”  

In a recent article, MJBiz.com refers to the day as “As the biggest shopping day of the year for the cannabis industry…” They say, leading up to 4/20/22 businesses were preparing by stocking more of their more perishable items such as rolled leaf.

Many dispensaries are providing discounts and sales this week to bolster even more traffic as the biggest shopping day of the year for the recreational sector of the industry peaks. Part of the preparation includes a focus on selling flower, mainly in the form of pre-rolls.

Just as Mother’s Day and Valentine’s is the high point of the year for selling roses and chocolate, the third week in April, the unofficial April 20 marijuana holiday resembles mainstream retail’s Black Friday shopping day after Thanksgiving in that consumers flock to cannabis stores to stock up on heavily discounted products. Most companies spend months preparing for this period.

The cannabis industry estimates that sales increase by about 30%-50% the week of 4/20. Using data from Headset, sales compared to an average week can be even higher. 

Broken out into product categories, the data forecasts week over average week increases of:

  • Vape Pen +92%
  • Pre-Rolls + 126%
  • Edibles +124
  • Flower +135%
  • Concentrate 152%

If 4/20 grows as the day to recognize the efforts of the counterculture and all subsequent movements to provide more freedom of choice, it will serve the industry well. Investors should take note, perhaps it could even become a benchmark for the cannabis business similar to Black Friday has for other retailers. I spoke with Justin Dye, Chairman and CEO of Schwazze (SHWZ). Schwazze is the largest cannabis company in Colorado by revenue. Justin was also busy with investors at NobleCon18, but took time to discuss the industry and the opportunity. Dye said, “The cannabis industry is maturing and a terrific growth sector.” He explained, “The industry is countercyclical, and trading at all-time lows. It is just a matter of time before meaningful catalysts such as safe banking regulation and continued legalization buoy the industry.”

Not unlike other industries that maintain their status most of the year, but have one or two celebrations that they “own,” The cannabis industry will certainly be well served by further elevating 4/20 as a day where even those that don’t partake all year long, participate in their own way.

Paul Hoffman

Managing Editor, Channelchek


Suggested Reading



Cannabis Legalization and the Road for Psychedelics

Psychedelic Laws and Investments May Follow Cannabis’ Success





Marijuana Hits the House This Spring

The Synergistic Effects of Crypto on Cannabis Businesses

 

Sources

https://mjbizdaily.com/how-cannabis-companies-are-capitalizing-on-420-amid-easing-covid-19-restrictions/

https://www.headset.io/solutions/retailers-and-dispensaries

https://www.vox.com/policy-and-politics/2019/4/19/18484698/what-is-420-meaning-marijuana-legalization

 

Stay up to date. Follow us:

 

Chakana Copper Corp (CHKKF)(PERU:CA) – Revised Option Agreement Significantly Enhances Financial Flexibility

Posted on by Admin

Tuesday, April 19, 2022

Chakana Copper Corp (CHKKF)(PERU:CA)
Revised Option Agreement Significantly Enhances Financial Flexibility

Noble Capital Markets research on Chakana Copper Corp is published under ticker symbols CHKKF and PERU:CA. The price target is in USD and based on ticker symbol CHKKF. Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the high-grade gold-copper-silver Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of high-grade gold-copper-silver mineralization hosted in tourmaline breccia pipes. A total of 33,353 metres of drilling has been completed to-date, testing nine (9) of twenty-three (23) confirmed breccia pipes with more than 92 total targets. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New payment terms. Chakana executed a binding agreement with Condor Resources Inc. to amend the terms of its Soledad purchase option agreement. Instead of making a US$4.425 million final payment on April 23, 2022, Chakana will complete the exercise of the option by either paying US$2.8 million and issuing 9,480,198 shares to Condor by June 23 or making cash and share payments to Condor over a three-year period.

    Drilling expected to resume in June.  In 2022, the company will likely conduct a 10,000-meter exploration drilling program to test 20 new targets. We expect the company’s geophysics program and target ranking to be completed shortly with drilling beginning in June using one rig. Outcomes from exploration drilling will likely determine high priority targets for a future resource drilling program …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Maple Gold Mines (MGMLF)(MGM:CA) – An Emerging World Class Gold Project in Quebecs Renowned Abitibi Greenstone Belt

Posted on by Admin

Tuesday, April 19, 2022

Maple Gold Mines (MGMLF)(MGM:CA)
 An Emerging World Class Gold Project in Quebec’s Renowned Abitibi Greenstone Belt

Maple Gold Mines Ltd. is a Canadian advanced exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited to jointly advance the district-scale Douay and Joutel gold projects located in the prolific Abitibi Greenstone Gold Belt of Quebec, Canada. The Company also holds an exclusive option to acquire 100% of the Eagle Mine Property located at Joutel.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating coverage. Maple Gold Mines is an exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited (NYSE: AEM, TSX: AEM), Canada’s largest gold producer and the third largest globally, to jointly explore the contiguous Douay and Joutel Gold projects located in Quebec’s renowned Abitibi Greenstone Belt. The projects represent a large and highly prospective land package encompassing 400 square kilometers, including an existing gold resource with significant expansion potential at Douay, along with the past producing Telbel and Eagle mines at Joutel. Maple Gold controls 100% of the Eagle mine.

    Significant resource expansion potential.  Recently released results from an updated NI 43-101 mineral resource estimate for the JV’s Douay gold project highlighted an increase in indicated and inferred gold ounces to 3.036 million from 2.774 million ounces. The estimate does not include results from the Fall 2021 drilling program …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Will the Fed Push Gold and Crypto Up by Raising its Inflation Target

Posted on by Admin 


Image: Marco Verch (Flickr)


Allianz Economist Explains His Thoughts on Gold and Crypto’s Future

 

Muhamed A. El-Arian is the Chief Economic Advisor at Allianz, (Allianz owns PIMCO). He said in an interview on CNBC he believes the Fed may have to raise its inflation target to 3%. The Fed’s current and ongoing inflation target is 2%. Recent inflation reports show YOY inflation at 8.5%. The Allianz economist sees prices increasing within the various asset classes that are generally seen as inflation hedges. This is why he is bullish on gold and cryptocurrencies.

Gold and cryptocurrency prices would increase if the Federal Reserve were to lift its inflation target as it engages in a prolonged fight to bring down consumer prices, economist Mohamed El-Erian told CNBC on Monday (April 18).  “They both go higher in a world like that,” he said, referring to the notion that the Fed may need to increase its long-term inflation target to 3% from 2%.

“What will force them to change their target is the recognition that by being so late, they can’t get to that target and their credibility is threatened,” said El-Erian. “They will also worry that by hitting the brakes too hard, they may push this economy not just into a short-term recession, but into a longer term recession.” Controlling inflation and calming markets while orchestrating price stability is tricky. El-Arian believes that the markets will view the Fed as being more credible if they set and attain a 3% target rather than fail at a 2% target while crippling the economy longer term. 

Currently, the FOMC Fed Chair Jay Powell is working to tamp down the rise in prices which is due to tight labor markets, supply chain issues, higher fuel demand with less fuel production, an increase in money supply, and an overall expectation of higher prices. Inflation in March beat a 40-year high at 8.5% year-over-year. The last time price increases were so rampant, Ronald Reagan had just begun occupying the oval office.

Last month the FOMC began what is being viewed as an interest rate-hike cycle when it raised the Fed Funds rate 25 basis points from a range of 0% to 0.25%. It has also begun tapering and will soon shrink its balance sheet which has the impact of taking cash out of the market which makes money more expensive (interest rates).

Impact on Gold and Crypto

Gold is considered a safe haven when there is uncertain global stability or a risk of higher prices. With the accelerated money creation attributed to the pandemic and the Russian invasion of Ukraine, gold prices have risen about 9% this year, trading at $1,960 per ounce. In contrast, bitcoin has decreased in value by 16% to $41,300 and ether has lost 21% to trade at $2,900.

Is crypto as good of a diversifier as precious metals? The Allianz economist said, “The concern for the crypto people is that this decline is happening at a time when gold is up and hitting almost $2,000,” He continued, “The big argument for crypto is it’s a diversifier — at a time of inflation, it is attractive.” But crypto hasn’t worked as a cushion recently, he said. “And that’s because crypto, unlike gold, benefited enormously from all the liquidity injections.

The way El-Arian reads the increase in gold and decline in crypto prices is there is a tug of war between the recognition that liquidity is going out from the system as a whole and attractiveness as a diversifier. He explained the liquidity element is winning out.

The Fed’s Inflation Target

El-Arian, as mentioned earlier believes that a credible target will comfort the markets compared to one that the Fed is less likely to attain soon. “What will force them to change their target is the recognition that by being so late, they can’t get to that target and their credibility is threatened,” said El-Erian. 

El-Arian told CNBC he would expect gold and crypto prices to rise if the Federal Reserve were to raise its inflation target to 3%.  

 

Suggested Reading:



Can One Wrong Board Member Cost Stockholders?

With the Russia-Ukraine War, Gold’s Safe-Haven Status Lasts





We Still Haven’t Reached the Inflation Finale

Was the Inflation of 1982 Like Today’s?

 

Sources

https://twitter.com/elerianm/status/1516319290605154309?ref_src=twsrc%5Etfw

https://www.cnbc.com/video/2022/04/18/we-are-nowhere-near-the-end-of-our-inflation-challenge-says-mohamed-el-erian.html

 

Stay up to date. Follow us: